Skip to main content
Figure 4 | Experimental Hematology & Oncology

Figure 4

From: Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report

Figure 4

New classification of MCD based on clinical and hystopatological features. Modified from: Kawabata H, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 2013, 53(1):57–61. IPL: Idiopathic Plasmacytic Lymphadenopathy; POEMS: Polyneuropathy, Organomegaly, Endocrinopathy/Edema, M-protein, Skin abnormalities; TAFRO: Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction and Organomegaly.

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us